OncoHub.ai
An abstract digest clustered by cancer type and ranked by clinical priority. Numerical results (HR, PFS, OS) are preserved; reliability caveats are embedded within each study's card.
Indication: 2L recurrent/metastatic ESCC after PD-1/L1 + platinum
Key finding: Median OS 9.8 vs 7.2 mo (HR 0.64, 95% CI 0.49–0.83; P=0.0004); median PFS 4.2 vs 2.0 mo (HR 0.50, 95% CI 0.40–0.63; P<0.0001); ORR 35.3% vs 13.1%; met both dual primary endpoints; G≥3 TRAE 85.1% vs 60.2%.
Clinical relevance: Supports iza-bren as a new 2L standard of care for ESCC.
Source: ASCO Abstract 4008
Indication: Intermediate-stage unresectable HCC
Key finding: Median PFS (BIRC, mRECIST) 11.1 vs 8.3 mo (HR 0.73, 95% CI 0.56–0.96; 1-sided p=0.0127); PFS by RECIST v1.1 13.9 vs 9.5 mo (HR 0.67); 24-mo OS 82.0% vs 73.3% (HR 0.76, 0.46–1.24, immature); G≥3 TRAE 73.7% vs 28.7%.
Clinical relevance: Clinically meaningful PFS gain; supports a new combination for TACE-eligible uHCC.
Source: ASCO Abstract 4001
Indication: 1L HER2-negative advanced/recurrent G/GEJ cancer
Key finding: Median PFS 9.0 vs 6.9 mo (HR 0.67, 90% CI 0.48–0.92; P=0.040); OS HR 0.60 (95% CI 0.37–0.96); ORR 62.0% vs 48.7%.
Clinical relevance: Adding an EP4 antagonist significantly improved PFS.
Source: ASCO Abstract 4007
Indication: 1L HER2-negative advanced/recurrent G/GEJ cancer
Key finding: OS HR 0.90 (95.8% CI 0.74–1.09; P=0.267); median OS 15.7 vs 15.8 mo; PFS HR 0.83 (0.69–1.00); ORR 57.9% vs 38.5%; G≥3 AE 80% vs 62.4%.
Clinical relevance: The triple combination did not improve OS over chemotherapy.
Source: ASCO Abstract 4006
Indication: LA/metastatic HCC progressing after atezolizumab+bevacizumab
Key finding: Median OS 14.6 vs 12.5 mo (HR 0.88, 95% CI 0.72–1.08; P=0.2115; did not meet primary endpoint); median DoR 10.2 vs 6.9 mo (HR 0.47).
Clinical relevance: A negative trial that provides a 2L benchmark after IO.
Source: ASCO Abstract 4002
Indication: 1L Claudin18.2-positive pancreatic (PC) and gastric (GC) cancer
Key finding: RP2D 800 μg/kg Q3W. PC: ORR 59.8%, DCR 89.0%, mPFS 8.74 mo, mOS 15.87 mo. GC: ORR 74.4%, DCR 93.0%, mPFS 10.09 mo; activity also in low Claudin18.2.
Clinical relevance: Phase 3 ongoing in pancreatic cancer.
Source: ASCO Abstract 4003
Indication: Refractory neuroendocrine carcinoma (NEC)
Key finding: Confirmed ORR 37.5% (30 mg) vs 21.9% (10 mg); in DLL3 ≥50% patients at 30 mg cORR 56.3%, mPFS 8.41 mo.
Clinical relevance: Supports the 30 mg dose for further development.
Source: ASCO Abstract 4004
Indication: Unresectable embolization-eligible HCC
Key finding: The combination with TACE improved clinical outcomes vs SOC (per ASCO Daily News headline); abstract full text not yet released at fetch time.
Clinical relevance: A potential new combination strategy for embolization-eligible HCC; verify against the full text.
Source: ASCO Abstract LBA4000
Indication: Resected NSCLC (EGFR/ALK-wild-type, ≥4 cm or LN+)
Key finding: Adjuvant nivolumab did not improve DFS vs observation (median DFS 71.3 vs 68.8 mo; HR 0.97, 95% CI 0.81–1.17, p=0.78); no benefit in the PD-L1 ≥50% subset (HR 0.86, 95% CI 0.59–1.25, p=0.43).
Clinical relevance: Questions the value of adjuvant IO after curative resection in this population.
Source: ASCO Abstract 8000
Indication: 2L small cell lung cancer with brain metastases
Key finding: CNS PFS 6.5 vs 4.2 mo (HR 0.40, 95% CI 0.24–0.66); CNS CR 15% vs 5%; OS in patients with baseline brain mets 13.9 vs 6.8 mo (HR 0.51, 95% CI 0.34–0.74).
Clinical relevance: Affirms tarlatamab as 2L SoC including patients with brain metastases.
Source: ASCO Abstract 8006
Indication: Resected stage IB(≥4cm)–IIIA EGFR-mutant NSCLC
Key finding: Adjuvant erlotinib did not improve OS (HR 0.89, 95% CI 0.59–1.34, 1-sided P=0.29); 5-yr OS 78.6% vs 77.9%; DFS improved (HR 0.74, 95% CI 0.55–1.01); trial stopped early due to osimertinib benefit.
Clinical relevance: No OS benefit; reinforces osimertinib as the adjuvant standard.
Source: ASCO Abstract 8001
Indication: Stage III ALK+ NSCLC, neoadjuvant
Key finding: pCR 46.9% (15/32), MPR 81.3%, R0 96.9%, ORR 83.7%; 1-yr EFS 97.1% (95% CI 91.5–100).
Clinical relevance: Met its primary endpoint; supports further investigation.
Source: ASCO Abstract 8002
Indication: R/R small cell lung cancer
Key finding: Monotherapy at 1.8 mg/kg as 2L: ORR 82%, mPFS 6.8 mo, mOS 14.3 mo; combination with budigalimab: ORR 55%, mPFS 8.1 mo.
Clinical relevance: Combinable with a checkpoint inhibitor; supports further development.
Source: ASCO Abstract 8008
Indication: Lung cancer screening (eligibility criteria)
Key finding: Time-since-smoking-duration (TSD) ≥20 yr made 59.4% of the cohort eligible vs 45.6% (2021 USPSTF pack-years); missed diagnoses 7.5% (TSD) vs 17.1% (2021 TPY) vs 30.3% (2013 TPY); TSD expanded eligibility by 28.8%.
Clinical relevance: TSD-based criteria may improve sensitivity and equity.
Source: ASCO Abstract 8004
Indication: 2L SCLC after chemo-IO
Key finding: 6-mo PFS 72.0%, ORR 61.7%, median PFS 9.8 mo (95% CI 6.7–13.4); G≥3 TRAE 26.7%.
Clinical relevance: Encouraging single-arm Phase 2 data.
Source: ASCO Abstract 8007
Indication: Lung cancer (epidemiology)
Key finding: Each SD increase in PM₂.₅: OR 1.048 (95% CI 1.035–1.061) for advanced-stage diagnosis; low-SES 69.7% vs 63.6% advanced-stage (p<0.001).
Clinical relevance: Environmental and social factors affect stage at diagnosis.
Source: ASCO Abstract 8003
Indication: Untreated advanced squamous NSCLC
Key finding: Ivonescimab + chemo improved OS vs tislelizumab + chemo (Daily News headline); statistics not provided in the source.
Clinical relevance: Potentially practice-changing in squamous NSCLC; verify against the full text.
Source: ASCO Daily News (HARMONi-6)
Indication: Extensive-stage SCLC (ES-SCLC)
Key finding: Phase 3 concurrent thoracic RT + chemo-IO; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA8005
Indication: Resected stage IIIB–IV cutaneous melanoma
Key finding: Intismeran + pembrolizumab vs pembrolizumab: RFS HR 0.51 (95% CI 0.29–0.89); DMFS HR 0.41 (95% CI 0.20–0.84); 5-yr OS 92.2% vs 71.3% (HR 0.47, 95% CI 0.17–1.35).
Clinical relevance: Sustained durable benefit of the personalized neoantigen vaccine combination.
Source: ASCO Abstract 9500
Indication: Locally advanced unresectable cutaneous SCC
Key finding: 18-mo EFS 86% (1-sided 95% CI lower bound 73%); 18-mo PFS 86%, OS 92%; pCR 32%.
Clinical relevance: Met its primary endpoint; supports combining cemiplimab with RT.
Source: ASCO Abstract 9506
Indication: Resectable stage IIIB-D melanoma
Key finding: pCR 63% (10/16), MPR 69%; 1 G5 myocarditis; no recurrences at median 9.8 mo.
Clinical relevance: Encouraging neoadjuvant triplet activity; fatal toxicity noted.
Source: ASCO Abstract 9501
Indication: High-risk resectable stage II cutaneous melanoma
Key finding: pCR 60% (12/20), MPR 65%; G3 TRAE 15%.
Clinical relevance: Feasibility and high pathologic response in the stage II setting.
Source: ASCO Abstract 9502
Indication: 2/3L ICI-progressed advanced non-uveal melanoma
Key finding: Confirmed ORR 67% (1 CR, 9 PR), DCR 93%; manageable safety, no ICANS; outpatient lymphodepletion and CNB-enabled manufacturing.
Clinical relevance: Supports a registrational study.
Source: ASCO Abstract 9507
Indication: Advanced melanoma (PRAME+)
Key finding: At RP2D, confirmed ORR 56% (1 CR, 17 PR), DCR 91%; median DoR 14.6 mo; median PFS 6.1 mo; median OS 16.2 mo.
Clinical relevance: Phase 3 SUPRAME underway.
Source: ASCO Abstract 9508
Indication: HLA-A2-negative metastatic uveal melanoma, 1L
Key finding: Darovasertib + crizotinib vs investigator's choice; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA9503
Indication: Merkel cell carcinoma with lymph-node metastases
Key finding: Adjuvant avelumab Phase 3; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA9504
Indication: Resected Merkel cell carcinoma
Key finding: Adjuvant pembrolizumab updated outcomes; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA9505
Indication: Advanced melanoma
Key finding: Autologous TIL Phase 2; full text was not available in the source.
Clinical relevance: Unclear; must be verified against the full text.
Source: ASCO Abstract LBA9509
Indication: Postoperative non-pCR esophageal carcinoma
Key finding: 3-yr RFS 78.5%, 3-yr OS 83.1%; T-cell responses in 100% (23/23); favorable vs historical CheckMate 577 3-yr RFS 43%.
Clinical relevance: Promising, but a non-randomized historical comparison.
Source: ASCO Abstract 2511
Indication: Pan-tumor (heavily pretreated)
Key finding: SCLC ORR 64.0% (75% at 6 mg/kg Q3W); breast cancer ORR 83.8%; ovarian 46.2%; non-squamous NSCLC 57.1%.
Clinical relevance: Broad and consistent cross-tumor activity.
Source: ASCO Abstract 3002
Indication: Advanced solid tumors
Key finding: Overall ORR 52.5%, DCR 81.4%; SCLC ORR 69.4%, 2L SCLC ORR 85.7%; RP2D 6.0 mg/kg Q3W; no ILD.
Clinical relevance: First-in-class CD56 ADC with notable SCLC activity.
Source: ASCO Abstract 3000
Indication: R/R small cell lung cancer and NEC
Key finding: SCLC at 4.0/4.5 mg/kg: ORR 71.1%, cORR 57.8%, mPFS 7.2 mo; NEC ORR 40.9%.
Clinical relevance: Phase 3 in preparation.
Source: ASCO Abstract 3001
Indication: R/M ovarian cancer
Key finding: Platinum-sensitive cORR 88.9%; platinum-resistant cORR 47.5%; RP3D 3.8 mg/kg D1Q3W.
Clinical relevance: Phase 3 in platinum-resistant ovarian cancer in preparation.
Source: ASCO Abstract 3003
Indication: NSCLC (translational)
Key finding: B7-H4 prognostic impact is compartment-dependent: stromal B7-H4+ ORR 65.0% vs 38.6% (p=0.010), OS 36.4 vs 13.1 mo (p=0.016); tumoral B7-H4+ predicted poor PFS (p=0.007).
Clinical relevance: Supports spatially-resolved biomarker selection for ADC±IO.
Source: ASCO Abstract 3004
Indication: KRAS G12D-mutant NSCLC
Key finding: ORR 38.5% (15/39), DCR 94.9%; RP2D 1200 mg QD.
Clinical relevance: Promising KRAS G12D inhibitor activity.
Source: ASCO Abstract 3006
Indication: KRAS G12D advanced solid tumors
Key finding: 96.8% target-lesion reduction at first scan; ORR 37.5% (450 mg), 31.3% (650 mg); DCR 87.5–93.8%; no DLTs.
Clinical relevance: Manageable safety; encouraging early reductions.
Source: ASCO Abstract 3007
Indication: KRAS G12D advanced cholangiocarcinoma (CCA) and colorectal cancer (CRC)
Key finding: CCA ORR 35.0%, DCR 95.0%, mPFS 6.3 mo; CRC ORR 11.4%, DCR 77.1%, mPFS 4.1 mo.
Clinical relevance: Activity in heavily pretreated cholangiocarcinoma is notable.
Source: ASCO Abstract 3008
Indication: Pan-tumor / precision oncology
Key finding: In FINHER, predicted HER2 added prognostic value (p=0.01), with trastuzumab benefit in HER2+/predicted-HER2+ (HR 0.35, 95% CI 0.15–0.83); TAILORx p-interaction 0.021.
Clinical relevance: DL pathology models may refine biomarker-based treatment selection.
Source: ASCO Abstract 3005
Indication: Highly emetogenic chemotherapy (HEC) CINV prevention
Key finding: DEX-sparing (single-day) and DEX-free were non-inferior to standard 4-day DEX: overall CR 72.4% vs 72.2% vs 70.1% (non-inferiority margin −12%).
Clinical relevance: Supports steroid-sparing antiemetic strategies, especially with chemo-IO.
Source: ASCO Abstract 12000
Indication: Cancer survivors (76% breast)
Key finding: YOCAS vs standard care: mood difference −5.08, anxiety −0.72, fatigue −1.49 (all p<0.05); mood/fatigue mediated ~25% of insomnia improvement.
Clinical relevance: Supports yoga referral for survivors with mood/sleep symptoms.
Source: ASCO Abstract 12004
Indication: Prostate cancer-related fatigue (CRF) on ADT/RT
Key finding: Methylphenidate-containing arms improved CRF vs placebo (FACIT-F coefficient 3.23, 95% CI 0.84–5.63, P=0.008); EX+MP was not superior to EX+placebo.
Clinical relevance: Methylphenidate-containing regimens improve CRF.
Source: ASCO Abstract 12005
Indication: Young-adult cancer patients
Key finding: Young adults experienced anxiety −0.195, depression −0.168 (p<0.0001); physical-function impairment worsened 0.101 (p=0.014); greater intervention effects vs ≥40y for depression, fatigue, pain, and physical-function impairment.
Clinical relevance: Supports ePROM-triggered care-coordination interventions for young adults.
Source: ASCO Abstract 12007
Indication: Care delivery / operations
Key finding: A CAR-T outpatient model reduced hospital days (Abstract 1503); a TRIAGE AI matching tool achieved 78.3% sensitivity / 98.5% specificity at the study threshold (Abstract 1501).
Clinical relevance: Operational innovations to reduce inpatient burden and improve trial matching.
Source: ASCO Abstracts 1503 / 1501
Indication: Adolescent/young-adult (AYA) cancer survivors
Key finding: Positive affect increased and anxiety decreased in most arms; no superiority of EMPOWER vs the control components.
Clinical relevance: Low-touch digital interventions are broadly helpful.
Source: ASCO Abstract 12006
Indication: Pan-tumor framework (TCGA analysis)
Key finding: 7.4% of patients (n=741) harbored tumor-suppressor neoantigens with matched synthetic-lethal vulnerabilities (4.6% hypomorphic, 2.8% null).
Clinical relevance: A framework for sequential vs upfront vaccine + SL-inhibitor strategies; prospective validation needed.
Source: ASCO Abstract 2510
Indication: mCRPC
Key finding: Preliminary safety/dosimetry of 177Lu-rosopatamab tetraxetan + SoC; full statistics were not in the provided content.
Clinical relevance: Awaiting the full readout.
Source: ASCO Abstract LBA5009
Indication: Supportive care (insomnia, CRF, pain, symptom support)
Key finding: Gabapentin+tramadol (LBA12001), Ramelteon (LBA12002), Bupropion for CRF (LBA12003), and SUPPORT+ (LBA12008); full text was not available in the source for any.
Clinical relevance: Unclear; must be verified against the full texts.
Source: ASCO Abstracts LBA12001-12003 / LBA12008
This report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.
OncoHub.ai · ASCO 2026 Gündem
Bu içerik editoryaldir. Tıbbi tavsiye değildir. Klinik karar hekime aittir.
oncohub.ai →